ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

HS-20093

Participants in all subjucts will receive HS-20093 at 10mg/kg

Trial Locations (25)

200120

RECRUITING

Shanghai East Hospital, Shanghai

Unknown

RECRUITING

Anhui Cancer Hospital, Hefei

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Beijing Tongren Hospital, CMU, Beijing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Sun Yai-Sen Memorial Hospital Sun Yai-Sen University, Guangzhou

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

RECRUITING

The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The Second XIANGYA Hospital Of Central South University, Changsha

NOT_YET_RECRUITING

The Second Hospital of Dalian Medical University, Dalian

RECRUITING

Liaoning Cancer Hospital, Shenyang

RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

RECRUITING

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

RECRUITING

The first Affiliated Hospital of Xi'an Jiaotong University, Xi’an

RECRUITING

Sichuan Cancer Hospital, Chengdu

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Tianjin Cancer Hospital, Tianjin

RECRUITING

Cancer hospital of Xinjiang medical University, Xinjiang

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY